Abeona Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
DALLAS, TX and NEW YORK, NY -- (Marketwired) -- 02/04/16 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Jeffrey Davis, COO, will be presenting for the company at the Annual BIO CEO & Investor Conference in New York City, NY on Monday, February 8th, 2016 at 4pm EST in The Duke of Windsor Room at The Waldorf Astoria.
Event: BIO CEO and Investor Conference
Date: Monday, February 8th, 2016
Time: 4:00pm EST
Location: The Waldorf Astoria, New York City
Room: Duke of Windsor
Webcast Link: http://www.veracast.com/webcasts/bio/ceoinvestor2016/97132155761.cfm
The presentation will be open to all interested investors through a live audio webcast accessible from http://www.veracast.com/webcasts/bio/ceoinvestor2016/97132155761.cfm.
An archived replay of the webcast will also be available for 90 days following the live presentation.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contact:
VP of Communications
Abeona Therapeutics, Inc.
Director of Investor Relations
Abeona Therapeutics, Inc.
Source: Abeona Therapeutics, Inc.
Released February 4, 2016